Ardelyx, Inc.
(NASDAQ : ARDX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.26%332.740.0%$4441.44m
BNTXBioNTech SE 2.48%269.380.0%$741.17m
NVAXNovavax, Inc. -14.38%137.4679.4%$608.81m
AMGNAmgen, Inc. 1.36%209.591.4%$553.74m
REGNRegeneron Pharmaceuticals, Inc. 1.80%562.042.7%$439.34m
SNSSSunesis Pharmaceuticals, Inc. 2.28%6.280.7%$439.00m
GILDGilead Sciences, Inc. -0.05%66.871.0%$412.87m
CCXIChemoCentryx, Inc. 3.48%34.822.9%$398.75m
ILMNIllumina, Inc. -0.13%413.533.3%$374.13m
XLRNAcceleron Pharma, Inc. -0.85%172.275.3%$347.36m
VRTXVertex Pharmaceuticals, Inc. -0.04%185.331.9%$269.64m
BIIBBiogen, Inc. -0.83%265.911.7%$241.52m
OCGNOcugen, Inc. 5.10%8.760.0%$185.52m
XENEXenon Pharmaceuticals, Inc. 1.41%30.230.4%$162.63m
CRSPCRISPR Therapeutics AG -1.77%98.490.6%$159.26m

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.